Loading...
•
Jun 30, 2021
Omega Therapeutics Q2 2021 Earnings Report
Omega Therapeutics reported financial results for the second quarter ended June 30, 2021.
Key Takeaways
Omega Therapeutics reported a net loss of $15.4 million for the second quarter of 2021. The company's cash and cash equivalents totaled $122.4 million as of June 30, 2021, which does not include the gross proceeds of $141.1 million from the Company’s IPO.
Cash and cash equivalents totaled $122.4 million as of June 30, 2021, not including $141.1 million gross proceeds from IPO.
IND submission for lead program, OTX-2002, for the treatment of Hepatocellular Carcinoma, remains on track for the first half of 2022.
Research and development expenses for the second quarter of 2021 were $11.2 million.
General and administrative expenses for the second quarter of 2021 were $3.6 million.